Skip to main content

Advertisement

SpringerLink
Log in

Current status and perspectives in cancer chemotherapy

  • Published:
Breast Cancer Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

New anticancer drugs with novel structures including paclitaxel, docetaxel, ilinotecan and gemcitabine have shown significant activity against various solid tumors in phase II trials. Phase II trials of combination regimens containing these drugs are currently in progress. Some combinations such as paclitaxel plus cisplatin in ovarian cancer have shown superiority over the past standard regimen. Not surprisingly, several analogues of these drugs have been developed and currently phase II trials are in progress. ET-743 may has some hope to become the first anticancer drug from a marine product. Oral chemotherapy is useful for treatment of outpatients. A combination regimen of UFT plus oral leucovorin has shown equivalent activity to 5-fluorouracil and leucovorin in advanced colorectal cancer, and capecitabine has shown superior activity and less toxicity than 5-fluorouracil and leucovorin in advanced colorectal cancer. Monoclonal antibody therapy has been successful in patients with breast cancer overexpressing HER2 and in patients with B-cell lymphoma. Currently clinical trials of 17-1A for colorectal cancer and HUM195 for acute myelogeneous leukemia are in progress. Recently presented results of angiogenesis inhibitors are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AC:

Adriamycin plus cyclophosphamide

AT:

Adriamycin plus taxotere

CHOP:

Cyclophosphamide, adriamycin, vincristine, prednisone

CPT:

Ilinotecan

T:

Taxol

References

  1. Rowinsky EK, Onetto N, Canetta RM,et al: Taxol; The first of the taxens, an important new class of antitumor agents.Semin Oncology 19:646–662, 1992.

    CAS  Google Scholar 

  2. Ettinger DS, Finkelstein DM, Sarma RP,et al: Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer; An Eeastern Cooperative Oncology Group Study.J Clin Oncol 13:1430–1435, 1995.

    PubMed  CAS  Google Scholar 

  3. Roth BJ, Dreicer R, Einhorn LH,et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium; A phase II trial of the Eastern Cooperative Oncology Group.J Clin Oncol 12:2264–2270, 1994.

    PubMed  CAS  Google Scholar 

  4. McGuire WP, Blessing JA, Moore D,et al: Paclitaxel has moderate activity in squamous cervix cancer; A Gynecologic Oncology Group Study.J Clin Oncol 14:792–795, 1996.

    PubMed  CAS  Google Scholar 

  5. Cortes JE, Pazdar R: Docetaxel.J Clin Oncol 13:2643–2655, 1995.

    PubMed  CAS  Google Scholar 

  6. Ogawa M: Novel anticancer drugs in Japan.J Cancer Res Clin Oncol 125:134–140, 1999.

    Article  PubMed  CAS  Google Scholar 

  7. Carmichael J, Passinger K, Philip P,et al: Advanced breast cancer; A phase II trial with gemicitabine.J Clin Oncol 13:2731–2736, 1995.

    PubMed  CAS  Google Scholar 

  8. Anderson H, Lund B, Bach F,et al: Single-agent activiy of weekly gemicitabine in advanced non-small-cell lung cancer; A phase II study. IIClin Oncol 12:1821–1826, 1994.

    CAS  Google Scholar 

  9. Moore MJ, Tannock IF, Frnst DS,et al: Gemicitabine; A promising new agent in the treatment of advanced urothelial cancer.J Clin Oncol 15:3441–3445, 1997.

    PubMed  CAS  Google Scholar 

  10. Cormier Y, Eisenhauer E, Gregg R,et al: Gemcitabine; An active new agent in patients (PTS) with previously untreated small cell lung cancer; A phase II trial of the NCI Canada Clinical Trials Group (NCIC CTG).Proc Am Soc Clin Oncol 12:330, 1993.

    Google Scholar 

  11. McGuire WP, Hoskins WJ, Brady M,et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage IE and stage IV ovarian cancer.N Engl J Med 334:1–6, 1996.

    Article  PubMed  CAS  Google Scholar 

  12. Nabhaltz JM, Falkson G, Campos D,et al: A phase HI trial comparing doxorubicin (A) and doxcetaxel (T)(AT) to doxorubicin and cyclophosphamide as first line chemotherapy for MBC.Proc Am Soc Clin Oncol 18:127a, 1999.

    Google Scholar 

  13. Henderson IC, Berry D, Demetri G,et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with nodepositive primary breast cancer (BC).Proc Am Soc Clin Oncol 17:101a, 1998.

    Google Scholar 

  14. Saltz LB, Locker PK, Pirotta N,et al: Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC).Proc Am Soc Clin Oncol 18:260a, 1999.

    Google Scholar 

  15. Sessa C, Cuvier C, Caldiera S,et al: A phase I clinical and pharmacokinetic (PK) study of RPR109881A, a new taxoid administered as a 1-hour infusion in patients (PTS) with solid tumors.Proc Am Soc Clin Oncol 18:189a, 1998.

    Google Scholar 

  16. Highley M, Sessa C, Hudhes A,et al: Phase I and pharmacokinetic (PK) study of BMS-184476, a new taxene analog, given weekly in patients with advanced malignancies.Proc Am Soc Clin Oncol 18:168a, 1999.

    Google Scholar 

  17. Hidalgo M, Aylesworth C, Rerrante K,et al: Phase I and pharmacokinetic (PK) study of BMS-184476, a potent and soluble taxene analog, as a 1-hour infusion every 3 weeks.Proc Am Soc Clin Oncol 18:168a, 1999.

    Google Scholar 

  18. Rowinsky E, Johnson T, Geyer C,et al: DX-89515, a hexacyclic camptothecin (CPT) analog on a daily × 5 day schedule; A phase I and pharmacokinetic (PC) study.Proc Am Soc Clin Oncol 18:164a, 1999.

    Google Scholar 

  19. Royce M, Lassere Y, Hoff P,et al: DX-89515, Phase I and pharmacokinetic study of a novel camptothecin analogue administered by 24-hour continuous infusion to patients with advanced solid tumors.Proc Am Soc Clin Oncol 18:177a, 1999.

    Google Scholar 

  20. Cvitkovic E, Riofrio M, Goodwasser F,et al: Final results of a phase I study of Ecteinascidin-743 (ET-743) 24-hour (h) continuous infusion in advanced solid tumors (AST) patients (PTS).Proc Am Soc Clin Oncol 18:180a, 1999.

    Google Scholar 

  21. Ryan DP, Supko JG, Eder JP,et al: A phase I and pharmacokinetic trial of Ecteinascidin-743 (ET-743) administered as a 72-hour continuous infusion.Proc Am Soc Clin Oncol 18:188a, 1999.

    Google Scholar 

  22. Pazdar R, Douillard J-Y, Slillings JR,et al: Multicenter phase HI study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer.Proc Am Soc Clin Oncol 18:263a, 1999.

    Google Scholar 

  23. Twelves C, Harper P, Vun Cutsen E,et al: A phase III trial (SO1496) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer.Proc Am Soc Clin Oncol 18:263a, 1999.

    Google Scholar 

  24. Cobleigh MA, Vogel CL, Tripathy D,et al: Efficacy and safety of Herceptin (humarized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer.Proc Am Soc Clin Oncol 17:97a, 1998.

    Google Scholar 

  25. Slamon D, Leyland-Jones B, Shak S,et al: Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + /MBC) markedly increases anticancer activity; A randomized multinational controlled phase HI trial.Proc Am Soc Clin Oncol 16:98a, 1998.

    Google Scholar 

  26. Norton L, Slamon D, Leyland-Jones B,et al: Overall survival (OS) advantage to simultaneous chemotherapy (CR+) plus the humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-over-expressing (HER2 + ) metastatic breast cancer (MBC).Proc Am Soc Clin Oncol 18:127a, 1999.

    Google Scholar 

  27. Maloney DG, Grillo-Lopez J, Whie CA,et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood 90:2188–2195, 1997.

    PubMed  CAS  Google Scholar 

  28. Piro LD, White CA, Grillo-Lopez AJ,et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low grade or follicular non-Hodgkin lymphoma.Ann Oncol 10:655–661, 1999.

    Article  PubMed  CAS  Google Scholar 

  29. Czuczman MS, Grillo-Lopez AJ, White CA,et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol 17:268–276, 1999.

    PubMed  CAS  Google Scholar 

  30. Reithmuller G, Holtz E, Schlimak G,et al: Monoclonal antibody therapy for resected Dukes’C colorectal cancer; Seven-year outcome at a multicenter randomized trial.J Clin Oncol 16:1788–1794, 1998.

    Google Scholar 

  31. Caron PC, Dumont L, Scheinberg DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HUM 195 in myelogenous leukemia.Clin Cancer Res 4:1421–1428, 1998.

    PubMed  CAS  Google Scholar 

  32. Feldman E, Kalaycio M, Schulman P,et al: Humanized monoclonal anti-CD33 antibody HUM 195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML); Preliminary report of a phase II study.Proc Am Soc Clin Oncol 18:4a, 1999.

    Google Scholar 

  33. Rosen L, Mulay M, Mayers A,et al: Phase I doseescalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies.Proc Am Soc Clin Oncol 18:161a, 1999.

    Google Scholar 

  34. Cropp G, Rosen L, Mulay M,et al: Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies.Proc Am Soc Clin Oncol 18:161a, 1999.

    Google Scholar 

  35. de Vries EGE, Groen HJM, Wynendaele W,et al: PMU-145156E—a novel angiogenesis inhibitor—in patients with solid tumors; An update of a phase I and pharmacokinetic study.Proc Am Soc Clin Oncol 18:161a, 1999.

    Google Scholar 

  36. Patnaik A, Rowinsky E, Harmond L,et al: A phase I and pharmacokinetic (PK) study of the unique angiogenesis inhibitor, squalamine lactate (MSI-1256E).Proc Am Soc Clin Oncol 18:162a, 1999.

    Google Scholar 

  37. Trocky N, Narshall J, Rizvi N,et al: A phase I safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion of MSI-1256F (squalamine lactate) in patients with advanced cancer.Proc Am Soc Clin Oncol 18:162a, 1999.

    Google Scholar 

  38. Goel R, Hirte H, Major P,et al: Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients.Proc Am Soc Clin Oncol 18:160a, 1999.

    Google Scholar 

  39. Tolcher A, Rowinsky E, Rizzo Z,et al: Phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay 12-9566 in combination with paclitaxel and carboplatin.Proc Am Soc Clin Oncol 18:160a, 1999.

    Google Scholar 

  40. D’Olimpio J, Hande K, Collier M,et al: Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors.Proc Am Soc Clin Oncol 18:160a, 1999.

    Google Scholar 

  41. Jones PH, Elliot M, Dobbs N,et al: Phase I / II study of combination angiogenesis therapy with marimastat, captopril and fragmin.Proc Am Soc Clin Oncol 18:447a, 1999.

    Google Scholar 

  42. Rosemurgy A, Buckels J, Charnley R,et al: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer.Proc Am Soc Clin Oncol 18:261a, 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aichi Cancer Center, 1-1 Kanokoden, 464-8681, Nagoya, Japan

    Makoto Ogawa

Authors
  1. Makoto Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Ogawa, M. Current status and perspectives in cancer chemotherapy. Breast Cancer 6, 270–274 (1999). https://doi.org/10.1007/BF02966438

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966438

Key words

Search

Navigation